Abstract Search

ea0022p424 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Serum concentration of o,p’DDD (mitotane), o,p’DDA and o,p’DDE as predictors of tumour response in adrenocortical carcinoma: results of a retrospective European Network for the Study of Adrenal Tumors (ENS@T) multicentre study

Hermsen Ilse , Fassnacht Martin , Terzolo Massimo , Houterman Saskia , Hartigh Jan den , Leboulleux Sophie , Daffara Fulvia , Allolio Bruno , Berruti Alfredo , Chadarevian Rita , Haak Harm , Baudin Eric

Introduction: O,pDDD is the drug of choice for patients with adrenocortical carcinoma (ACC). Monitoring o,pDDD serum level has been proposed as predictor of tumour response. Measurement of o,pDDD metabolites involved in the active pathway may provide an improved prediction of o,pDDD activity. The objective of our study was to (1)to confirm the currently used threshold o,pDDD serum level of 14mg/l for achieving a tumour response and (2)compare the ...

0 shares

Endocrine Abstracts

Serum concentration of o,p’DDD (mitotane), o,p’DDA and o,p’DDE as predictors of tumour response in adrenocortical carcinoma: results of a retrospective European Network for the Study of Adrenal Tumors (ENS@T) multicentre study

BiosciAbstracts